296 related articles for article (PubMed ID: 10544608)
1. [Clinical course, morphology and prognosis of chronic myelomonocytic leukemia].
Germing U; Strupp C; Meckenstock G; Giagounidis A; Minning H; Aul C
Med Klin (Munich); 1999 Sep; 94(9):467-72. PubMed ID: 10544608
[TBL] [Abstract][Full Text] [Related]
2. Problems in the classification of CMML--dysplastic versus proliferative type.
Germing U; Gattermann N; Minning H; Heyll A; Aul C
Leuk Res; 1998 Oct; 22(10):871-8. PubMed ID: 9766745
[TBL] [Abstract][Full Text] [Related]
3. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease?
Voglová J; Chrobák L; Neuwirtová R; Malasková V; Straka L
Leuk Res; 2001 Jun; 25(6):493-9. PubMed ID: 11337023
[TBL] [Abstract][Full Text] [Related]
5. Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution.
Nösslinger T; Reisner R; Grüner H; Tüchler H; Nowotny H; Pittermann E; Pfeilstöcker M
Leuk Res; 2001 Sep; 25(9):741-7. PubMed ID: 11489467
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of granulocyte-macrophage colony formation in chronic myelomonocytic leukemia: a comparative study with other myelodysplastic and myeloproliferative disorders.
Yuo A; Miyazono K; Urabe A; Takaku F
Jpn J Cancer Res; 1990 Aug; 81(8):820-6. PubMed ID: 2118895
[TBL] [Abstract][Full Text] [Related]
7. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
Michaux JL; Martiat P
Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
[TBL] [Abstract][Full Text] [Related]
8. [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification].
Fukuhara T; Kakinoki Y
Rinsho Byori; 2006 Mar; 54(3):243-9. PubMed ID: 16637572
[TBL] [Abstract][Full Text] [Related]
9. Chronic myelomonocytic leukemia: lost in classification?
Bowen DT
Hematol Oncol; 2005 Mar; 23(1):26-33. PubMed ID: 16149105
[TBL] [Abstract][Full Text] [Related]
10. Risk assessment in chronic myelomonocytic leukemia (CMML).
Germing U; Kündgen A; Gattermann N
Leuk Lymphoma; 2004 Jul; 45(7):1311-8. PubMed ID: 15359628
[TBL] [Abstract][Full Text] [Related]
11. Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China.
Chen B; Ma Y; Xu X; Wang X; Qin W; Ji M; Lin G
Leuk Res; 2010 Apr; 34(4):458-62. PubMed ID: 19631982
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution.
Nösslinger T; Reisner R; Koller E; Grüner H; Tüchler H; Nowotny H; Pittermann E; Pfeilstöcker M
Blood; 2001 Nov; 98(10):2935-41. PubMed ID: 11698274
[TBL] [Abstract][Full Text] [Related]
13. Models of Prognostication in Chronic Myelomonocytic Leukemia.
Onida F
Curr Hematol Malig Rep; 2017 Dec; 12(6):513-521. PubMed ID: 29064026
[TBL] [Abstract][Full Text] [Related]
14. Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center.
González-Medina I; Bueno J; Torrequebrada A; López A; Vallespí T; Massagué I
Leuk Res; 2002 Sep; 26(9):821-4. PubMed ID: 12127557
[TBL] [Abstract][Full Text] [Related]
15. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
16. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.
Onida F; Kantarjian HM; Smith TL; Ball G; Keating MJ; Estey EH; Glassman AB; Albitar M; Kwari MI; Beran M
Blood; 2002 Feb; 99(3):840-9. PubMed ID: 11806985
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Characteristics and Survival Analysis of Patients with Chronic Myelomonocytic Leukemia].
Wang JY; Chen JF; Wang SF; Guo QH; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):476-482. PubMed ID: 37096522
[TBL] [Abstract][Full Text] [Related]
19. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
